<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447161</url>
  </required_header>
  <id_info>
    <org_study_id>ENTER_L_01125</org_study_id>
    <nct_id>NCT00447161</nct_id>
  </id_info>
  <brief_title>Preventing Antibiotic-Associated DiarRhea Using Erceflora</brief_title>
  <acronym>PADRE</acronym>
  <official_title>Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To determine the effectiveness of the pre-biotic Bacillus clausii in preventing antibiotic
      associated diarrhea among hospitalized immunocompetent Filipino children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the incidence of antibiotic-associated diarrhea (relative risk)</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All adverse event regardless of seriousness or relationship to the study drug</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in the number of antibiotic-associated diarrhea events per day</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the severity of diarrhea events</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Gastrointestinal-related symptoms (nausea, vomiting, abdominal pain)over-all reduction in the number of hospitalization days beween control and treatment groups.</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in C. dificille -associated diarrhea.</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Diarrhea, Infantile</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bacillus Clausii Multi ATB Resist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacillus Clausii Multi ATB Resist</intervention_name>
    <description>Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically stable children with mild to moderate illness admitted for treatment of
             bacterial infection.

        Exclusion Criteria:

          -  Children with unstable medical condition

          -  In any form of immunocompromized state

          -  With contraindication to take medication

          -  Has taken antibiotics for 3 weeks before start of trial.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paz Figueroa</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2007</study_first_posted>
  <last_update_submitted>September 4, 2008</last_update_submitted>
  <last_update_submitted_qc>September 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Diarrhea, Infantile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

